Diffuse Astrocytic and Oligodendroglial Tumors in Adults
Key Points
Key Points
- Each year, more than 15,000 people in the United States are newly diagnosed with diffuse astrocytic and oligodendroglial tumors, including glioblastoma.
- Recently, several systemic agents and a device have demonstrated improvements in survival when added to surgical and radiation therapies.
- Genetic alterations, specifically Isocitrate Dehydrogenase 1 and 2 (IDH1 and IDH2), have become critical classification and prognostic biomarkers.
Treatment
...eatment...
...tant Astrocytic and Oligodendroglia...
...godendroglioma, IDH-mutant, 1p/19q co-deleted, CNS...
...mendation 1.1People with oligodendroglioma, IDH-mu...
...zolomide is a reasonable alternative to PCV when...
...ation 1.2Within the group of people with oligoden...
Oligodendroglioma, IDH-mutant, 1p/19q co-deleted,...
...mendation 1.3People with oligodendrogl...
...ide is a reasonable alternative to...
...DH-mutant, 1p/19q non-codeleted, CNS WHO grade...
...on 1.4People with astrocytoma, IDH-mut...
...mmendation 1.5In astrocytoma, IDH-mutant...
Astrocytoma, IDH-mutant, 1p/19q non-c...
...ion 1.6People with astrocytoma, IDH-mu...
...ma, IDH-mutant, CNS WHO grade 4 (former IDH-mutant...
...ion 1.7People with astrocytoma, IDH-mutan...
Glioblastoma and Other IDH-wildtype Diffuse Gli...
...ation 2.1People with astrocytomas, I...
...commendation 2.2Concurrent temozolomide an...
...ndation 2.3Six months of adjuvant temozolomide s...
...dation 2.4Alternating electric field therapy...
...mendation 2.5Bevacizumab is NOT rec...
...2.6In people with glioblastoma, IDH-wil...
...ndation 2.7In people with glioblastoma, I...
...2.8No recommendation for or against any therapeu...
...with recurrent glioblastoma should be...
...2.9No recommendation for or against any therape...
...with diffuse midline glioma should be referred for...
Table 1. Reasonable Doses and Schedules by Recommendation
...Reasonable Doses and Schedules by Recomm...